Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parenteral Drugs (India)'s gross profit for the
three
months ended in Mar. 2022 was ₹0.16 Mil. Parenteral Drugs (India)'s gross profit for the trailing twelve months (TTM) ended in Mar. 2022 was ₹30.31 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Parenteral Drugs (India) had a gross margin of 0.88% for the quarter that ended in Mar. 2022 => No sustainable competitive advantage
Parenteral Drugs (India) Gross Profit Related Terms
Parenteral Drugs (India) Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:PDPL vs ZTS, CTLT, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parenteral Drugs (India) Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Gross Profit distribution charts can be found below:
* The bar in red indicates where Parenteral Drugs (India)'s Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30.31 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Parenteral Drugs (India) (NSE:PDPL) has a Gross Profit of ₹30.31 Mil as of Mar. 2022. Gross Profit equals net sales less total cost of goods sold. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Gross Profit too high?
Parenteral Drugs (India)'s current Gross Profit is ₹30.31 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Gross Profit compare to ZTS and CTLT?
Parenteral Drugs (India)'s Gross Profit of ₹30.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Gross Profit is ₹30.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Gross Profit of ₹30.31 Mil. The current Gross Profit is ₹30.31 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Gross Profit is ₹30.31 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score
Get the complete analysis for NSE:PDPL
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PDPL has been successfully added to your 
